ReclastTreatment for Paget's Disease, Prevention of Osteoporosis, Prevention of Fractures
Update: Reclast Now FDA Approved - April 16, 2007
Novartis receives approvable letter" from the FDA for zoledronic acid 5 mg in the treatment of Paget's disease of the bone"
BASEL, Switzerland, February 24, 2006 - Novartis announced today that it has received an "approvable letter" from the US Food and Drug Administration (FDA) for zoledronic acid (5mg infusion), which is under review for the treatment of Paget's disease of the bone. Paget's disease is a chronic and sometimes painful disorder affecting more than one million people in the US.
The "approvable letter" is a notification that the FDA is prepared to approve the drug and contains conditions that the applicant must meet prior to obtaining final US marketing approval. This is the second approvable letter received for zoledronic acid for this indication. In this case, the FDA has requested additional data from the ongoing clinical trial program in osteoporosis.
Novartis is confident that providing this additional information to the FDA will help obtain final approval by the end of 2006 and allow this important therapy to be offered to patients living with Paget's disease. Submission for osteoporosis in the US and EU remains planned for 2007. Zoledronic acid 5 mg, under the trade name Aclasta, has been approved in 41 countries worldwide, including the EU, for the treatment of Paget's disease.
Posted: February 2006
- FDA Approves Reclast to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing - June 1, 2009
- FDA broadens US indication for once-yearly Reclast as only osteoporosis treatment approved for prevention of fractures after a hip fracture - June 5, 2008
- Reclast Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis - August 20, 2007
- Reclast Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone - April 17, 2007